OYE Therapeutics Raises $5.475M Series A to Advance High-Concentration Caffeine Therapy for Anesthesia Recovery and Opioid Overdose

OYE Therapeutics, a clinical-stage biopharmaceutical company headquartered in Crown Point, Indiana, has secured $5.475 million in Series A funding to advance the clinical development of its high-concentration intravenous caffeine therapy designed for anesthesia recovery and opioid-induced respiratory depression (OIRD). The oversubscribed financing round, completed in late 2025, will support the company’s transition into clinical trials and broader translational efforts aimed at addressing critical unmet medical needs in perioperative and acute care settings.

The Series A financing will enable OYE Therapeutics to move its lead investigational therapy into a Phase 1 clinical trial, expected to begin in the first quarter of 2026, with clinical objectives focused on pharmacokinetics, safety, and initial efficacy in healthy volunteers, followed by studies in contexts that simulate fentanyl intoxication. This data will form part of the regulatory strategy for advancing toward a 505(b)(2) submission pathway with the U.S. Food and Drug Administration.

While specific venture firms backing the round have not been publicly detailed, OYE Therapeutics’ investor base includes life sciences investment syndicates such as AngelMD and Keiretsu Forum, both known for supporting early-stage healthcare and biotechnology companies. These investors have previously participated in financing rounds that helped position the company for its current Series A and emerging clinical milestones.

In addition to the Series A financing, OYE Therapeutics recently completed a $5 million convertible note financing that was oversubscribed, signaling strong confidence from existing and new backers in the company’s science and clinical direction. The proceeds from this convertible note will advance OYE’s Phase 1 pharmacokinetic and safety program and support subsequent pivotal trials that form the backbone of its multitrack clinical development strategy.

OYE Therapeutics’ proprietary high-concentration caffeine platform is being developed to accelerate emergence from general anesthesia—a challenge that currently lacks approved pharmacologic treatments—and to support respiratory drive and wakefulness during recovery from opioid overdose when used in conjunction with naloxone. The company’s lead candidate aims to reduce recovery room time for surgical patients while addressing the persistent respiratory depression that can occur after opioid administration. This dual-use approach extends to both civilian healthcare and military acute care environments.

OIRD remains a significant clinical challenge, particularly in settings where opioids are widely used for pain management, sedation, or anesthesia, and where respiratory depression is a leading contributor to adverse events. By stimulating central nervous system activity and enhancing respiratory drive, OYE Therapeutics’ caffeine-based therapy could offer clinicians an adjunctive tool to improve patient outcomes, especially in scenarios where naloxone’s effects are limited by its shorter duration of action.

The Series A capital will also support expanded chemistry, manufacturing, and controls (CMC) activities, regulatory preparation, and the generation of early clinical data needed to attract additional strategic and financial partners as OYE approaches key inflection points in its development program. With these resources, the company plans to build on its translational research and bolster the infrastructure necessary to execute a comprehensive clinical strategy across its lead and potential follow-on indications.

OYE Therapeutics was founded with a mission to tackle clinical problems that have long been viewed as “accepted-as-intractable,” applying novel formulations and translational science to deliver solutions that improve patient care. The name “OYE,” short for “Open Your Eyes,” reflects the company’s focus on restoring consciousness and neurologic function at critical moments in medical care. Its development efforts are grounded in robust preclinical research and collaborations that include strategic engagement with military co-development partners, bringing both scientific insight and non-dilutive funding to support its path toward clinical validation.

As OYE Therapeutics prepares to enter clinical testing in 2026, investors and the broader healthcare community will be watching to see whether its high-concentration caffeine therapy can deliver meaningful improvements in anesthesia recovery and emergency care, particularly in the context of opioid overdose reversal—a field urgently in need of new tools. The successful Series A financing round positions the company to advance toward these goals with strengthened financial backing and clinical focus.